{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 42 of 51', 'Study ID RCB: 2020-A00652-37', \"understand, and obtain the patient's (and if applicable, the patient's assent and the legal\", \"guardian's) written consent before collection by LEO of identifiable patient information\", '(hereinafter referred to as personal data). The patient (or legal guardian) must agree that', 'his/her data will be processed, stored and may be transferred to third parties, e.g. other', 'companies or authorities, that may be located in other countries with potentially different', 'regulations for data. Additionally the patient (or legal guardian) must agree that his/her data', 'will be transferred to LEO HQ and used for multinational analysis. Before consenting, the', 'patient (and if applicable, legal guardian) must be given sufficient time to consider and to pose', 'questions. Since the study is observational, the consent only concerns the data collection per', 'se and is not consent to any interventional procedure or treatment.', 'The patient or legal guardian, if applicable, has the right to withdraw his/her consent at any', 'time without prejudice. In the Informed Consent Form it is stated that if consent is withdrawn,', 'any data collected before withdrawal of consent will be kept. The original, signed Informed', 'Consent Forms must be kept on the Site.', 'Data erroneously collected from patients for which written consent is not available, will not be', 'included in or will be deleted from the database, as feasible.', 'For details, see the Patient Information Sheet and Informed Consent Form.', 'This study will be conducted in accordance with the current version of the Declaration of', 'Helsinki (World Medical Association, 2013), The European Federation of Pharmaceutical', 'Industries and Associations (EFPHIA) HCP Code, Article 15 Non-interventional Studies of', 'Marketed Medicines (The European Federation of Pharmaceutical Industries and Associations,', '2008), Good Pharmacoepidemiology Practices (Public Policy Committee, 2016) and any local', 'regulations. Special attention will be paid to data privacy protection; General Data Protection', 'Regulation (GDPR (European Commission, 2016)), LEO Pharma A/S, Industriparken 55,', 'Ballerup will be the data holder.', 'LEO/CLINACT will ensure that the protocol and any amendments and the Patient Information', 'Sheet/Informed Consent Form, Diary and Questionnaires are submitted to the relevant', 'Independent Ethics Committees (IECs) and/or competent authorities and/or other national or', 'regional authorities according to local requirements. According to applicable regulations, LEO,', 'CLINACT will submit required documents to the IEC, such as:', 'periodic updates on the progress of the study', 'notification of the end-of-study', 'a summary of the study results', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 43 of 51', 'Study ID RCB: 2020-A00652-37', 'LEO will keep a copy of all documents submitted and an updated list of all submission and', 'approval dates of all documents submitted to the IEC and/or authorities and will provide the', 'Site Responsible with a copy of this list. Copies of the documents will be distributed upon', 'request.', 'None of the data planned to be collected are expected to have any psychological impact on', 'the participants, and the questions posed will be presented in a non-judgmental, objective', \"manner so that the impact on the patient's behaviour and honesty in data reporting is\", 'minimized. The nature of the collected data will not make it possible to track the patients', 'without access to the participant lists and Consent Forms stored at the Study Site. The', 'collection of this data is considered ethically justified, based on these precautions and the', 'following considerations.', 'This study focuses on collecting data on the real-life experience of biologic treated psoriasis', 'patients for up to 56 weeks.', 'It will be a challenge to keep patients motivated to contribute data to the study long-term,', 'but psoriasis patients are generally very willing to share their experience with those lending', 'non-judgmental ears to their experience.', 'The Site Study Responsible must give the patient oral and written information about the study', \"in a form that the patient can understand, and obtain the patient's written consent before\", 'collection of identifiable patient information (hereinafter referred to as personal data). Before', 'consenting, the patient must be given sufficient time to consider and to pose questions. Since', 'the study is observational the consent only concerns the data collection per se and is not', 'consent to any interventional procedure or treatment.', 'The patient must agree that his/her data will be transferred to LEO and processed and stored,', 'and shared with other business partners responsible for Kyntheum in other markets. In', 'addition, the patient must agree that authorized representatives from LEO or local authorities', 'with inspection rights get access to their consent documentation and medical records for', 'quality checks on protocol compliance and the data entries if requested. Written informed', 'consent to use of collected data must always be obtained before collection of any personal,', 'sensitive data. Data erroneously collected from patients for which written consent is not', 'available, will not be included in or will be deleted from the database, as feasible.', 'The patient has the right to withdraw his/her consent at any time without prejudice. In the', 'Informed Consent Form it is stated that if consent is withdrawn, any data collected before', 'withdrawal of consent will be kept. The original, signed Informed Consent Forms must be kept', 'on the Site.', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}